Search alternatives:
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 50 n (Expand Search)
ng decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
50 nn » 50 ns (Expand Search), 50 ng (Expand Search), 50 n (Expand Search)
-
61
-
62
Predicting pattern diversity decreases as a function of and .
Published 2025“…<p>For 50 Erdős-Rényi graphs with 30 nodes and 70 edges, we split the results into two columns according to the two initial degenerate unstable eigenmodes + : on the left, (if ), and on the right, (if ). …”
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
78
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
79
Flow chart of the study procedures.
Published 2023“…Pre-treatment spontaneous decrease of RPR titer was associated with a slower decrease in post-treatment RPR titer.…”
-
80